Effectiveness of levonorgestrel implant and depot medroxyprogesterone acetate injectable for women living with HIV on efavirenz: a prospective cohort study.
UNC Libraries · 16.07.2026
DOI: 10.17615/wps5-5w40 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift UNC Libraries, erschienen am 16.07.2026. Verfasst von Brian W. Pence und 17 weiteren Autor:innen.
Abstract (Originalsprache)
OBJECTIVE: We compared the contraceptive effectiveness of typical-use LNG implant and depot medroxyprogesterone acetate (DMPA) injectable during efavirenz use. DESIGN: We conducted a prospective cohort study of women living with HIV (WLHIV) on efavirenz-containing antiretroviral treatment in Lilongwe, Malawi. Eligible participants were 18-40 years of age and initiating LNG implant or DMPA injectable with desire to prevent pregnancy for 4+ years. Study visits and urine pregnancy testing occurred at enrollment, week 4, and every 24 weeks up to week 192. Malawi's efavirenz-to-dolutegravir transition shortened our duration of efavirenz follow-up. METHODS: Pregnancy incidence rates/100 person-years (PY) and an incidence rate difference (IRD) were estimated using an inverse-probability-weighted Poisson model. RESULTS: We enrolled 1,179 WLHIV on efavirenz: 592 and 587 chose to initiate the LNG implant and DMPA, respectively. Median follow-up during efavirenz use was 1.1 years (IQR: 0.5-1.7). Estimated pregnancy incidence rates were 6.6/100 PY (95%CI: 5.0, 8.7) in the LNG implant enrollment group (50 pregnancies) and 7.3/100 PY (95%CI: 5.5, 9.7) in the DMPA enrollment group (54 pregnancies), IRD -0.7/100 PY (95%CI: -3.5, 2.0). Results were similar in an analysis of first incident pregnancy during continued typical use of LNG implant (5.7/100 PY) versus continued typical use of DMPA (5.7/100 PY), IRD 0.0/100 PY (95%CI: -2.6, 2.7). CONCLUSIONS: In many settings, LNG implant has better contraceptive effectiveness than DMPA injectable. However, for WLHIV on efavirenz, we observed similar typical-use effectiveness for LNG implant versus provider-administrated DMPA injectable during the initial 1-2 years of use.
Schlagwörter
Zitieren
APA
Pence, B. W., Mollan, K. R., Tang, J. H., Chiwoko, J., Pettifor, A. E., Cottrell, M. L., Hudgens, M. G., Jonsson-Funk, M., Winston, J., Diepstra, K. L., Phiri, S., Lemani, C., Bula, A. K., Westreich, D. J., Hosseinipour, M. C., Chinula, L., Hagey, J. M., & Chapola, J. C. (2026). Effectiveness of levonorgestrel implant and depot medroxyprogesterone acetate injectable for women living with HIV on efavirenz: a prospective cohort study. UNC Libraries. https://doi.org/10.17615/wps5-5w40
Vancouver
Pence BW, Mollan KR, Tang JH, Chiwoko J, Pettifor AE, Cottrell ML, et al. Effectiveness of levonorgestrel implant and depot medroxyprogesterone acetate injectable for women living with HIV on efavirenz: a prospective cohort study. UNC Libraries. 2026. doi:10.17615/wps5-5w40
BibTeX
@article{Pence2026,
author = {Pence, Brian W. and Mollan, Katie R. and Tang, Jennifer H and Chiwoko, Jane and Pettifor, Audrey E. and Cottrell, Mackenzie Leigh and Hudgens, M G and Jonsson-Funk, Michele and Winston, Jennifer and Diepstra, Karen L. and Phiri, Sam and Lemani, Clara and Bula, Agatha Kapatuka and Westreich, Daniel J. and Hosseinipour, Mina C. and Chinula, Lameck and Hagey, Jill M. and Chapola, John Chawezi},
title = {Effectiveness of levonorgestrel implant and depot medroxyprogesterone acetate injectable for women living with HIV on efavirenz: a prospective cohort study},
journal = {UNC Libraries},
year = {2026},
doi = {10.17615/wps5-5w40}
}
EUVIMED